Renovacor, Inc.
(NYSE Amex Equities : RCOR)

( )
RCOR PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.87%285.761.5%$877.84m
GILDGilead Sciences, Inc. -0.19%87.791.0%$684.30m
MRNAModerna, Inc. 3.15%179.000.0%$651.73m
REGNRegeneron Pharmaceuticals, Inc. 2.25%764.272.6%$499.64m
VRTXVertex Pharmaceuticals, Inc. 1.85%317.581.9%$473.10m
BIIBBiogen, Inc. 0.23%292.151.8%$407.81m
ILMNIllumina, Inc. 1.23%208.523.2%$225.94m
BMRNBioMarin Pharmaceutical, Inc. 1.44%103.694.2%$162.19m
BNTXBioNTech SE 0.63%162.630.0%$150.70m
AXSMAxsome Therapeutics, Inc. 3.85%78.161.6%$146.95m
SNSSSunesis Pharmaceuticals, Inc. -3.98%1.930.7%$134.91m
RXDXPrometheus Biosciences, Inc 165.67%95.801.4%$103.84m
MRTXMirati Therapeutics, Inc. -30.66%49.591.6%$102.08m
HALOHalozyme Therapeutics, Inc. 2.41%57.7418.4%$82.03m
NVAXNovavax, Inc. 2.62%17.2275.3%$81.88m

Company Profile

Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA.